Baseline Characteristics of Included Studies.

Abbreviations: pts, patients; IHC, immunohistochemistry; HE, staining Hematoxylin-eosin staining; FOXP3, regulatory T-lymphocytes expressing forkhead box P 3 protein; NAC, neoadjuvant chemotherapy; CEF, cyclophosphamide/epirubicin/fluorouracil; CEX, epirubicin/cyclophosphamide/capecitabine; DC, docetaxel/carboplatin; EC, epirubicin/cyclophosphamide; EC-T, epirubicin/cyclophosphamide-taxane; CEF-T, cyclophosphamide/epirubicin/fluorouracil-taxane;T AC, docetaxel/doxorubicin/cyclophosphamide; NX, vinorelbine/capecitabine; TET, docetaxel-docetaxel/epirubicin; AC, doxorubicin/cyclophosphamide; AC-T, doxorubicin/cyclophosphamide-taxane; AD, doxorubicin/docetaxel; AT, doxorubicin/taxane; EC-TX, epirubicin/cyclophosphamide-docetaxel/capecitabine; EC-T-X, epirubicin/cyclophosphamide-docetaxel-capecitabine; PM, paclitaxle/non-pegylated liposomal doxorubicin; PMCb, paclitaxle/non-pegylated liposomal doxorubicin/carboplatin; H, trastuzumab; Bev, bevacizumab; L, lapatinib; EVE, everolimus; IS =  Intratumoral sites; SS =  stromal sites;BS, both sites;10% INC, 10 increment
a, GeparDuo.
b, GeparTrio.
Baseline Characteristics of Included Studies.

缩写说明：pts：患者（patients）；IHC：免疫组织化学（immunohistochemistry）；HE：苏木精-伊红染色（Hematoxylin-eosin staining）；FOXP3：表达叉头框P3蛋白的调节性T淋巴细胞（regulatory T-lymphocytes expressing forkhead box P 3 protein）；NAC：新辅助化疗（neoadjuvant chemotherapy）；CEF：环磷酰胺/表柔比星/氟尿嘧啶（cyclophosphamide/epirubicin/fluorouracil）；CEX：表柔比星/环磷酰胺/卡培他滨（epirubicin/cyclophosphamide/capecitabine）；DC：多西他赛/卡铂（docetaxel/carboplatin）；EC：表柔比星/环磷酰胺（epirubicin/cyclophosphamide）；EC-T：表柔比星/环磷酰胺-紫杉类（epirubicin/cyclophosphamide-taxane）；CEF-T：环磷酰胺/表柔比星/氟尿嘧啶-紫杉类（cyclophosphamide/epirubicin/fluorouracil-taxane）；TAC：多西他赛/多柔比星/环磷酰胺（docetaxel/doxorubicin/cyclophosphamide）；NX：长春瑞滨/卡培他滨（vinorelbine/capecitabine）；TET：多西他赛-多西他赛/表柔比星（docetaxel-docetaxel/epirubicin）；AC：多柔比星/环磷酰胺（doxorubicin/cyclophosphamide）；AC-T：多柔比星/环磷酰胺-紫杉类（doxorubicin/cyclophosphamide-taxane）；AD：多柔比星/多西他赛（doxorubicin/docetaxel）；AT：多柔比星/紫杉类（doxorubicin/taxane）；EC-TX：表柔比星/环磷酰胺-多西他赛/卡培他滨（epirubicin/cyclophosphamide-docetaxel/capecitabine）；EC-T-X：表柔比星/环磷酰胺-多西他赛-卡培他滨（epirubicin/cyclophosphamide-docetaxel-capecitabine）；PM：紫杉醇/非聚乙二醇化脂质体多柔比星（paclitaxel/non-pegylated liposomal doxorubicin）；PMCb：紫杉醇/非聚乙二醇化脂质体多柔比星/卡铂（paclitaxel/non-pegylated liposomal doxorubicin/carboplatin）；H：曲妥珠单抗（trastuzumab）；Bev：贝伐珠单抗（bevacizumab）；L：拉帕替尼（lapatinib）；EVE：依维莫司（everolimus）；IS：瘤内位点（Intratumoral sites）；SS：间质位点（stromal sites）；BS：双位点（both sites）；10% INC：10%增量（10 increment）。注：a代表GeparDuo研究，b代表GeparTrio研究。纳入研究的基线特征。